The existence of a form of ALS in which PP2A is upregulated, one of the neurodegenerative diseases for which Sephin1 has a therapeutic effect, supports the validity that one of the molecular targets of Sephin1 is PP2A holoenzyme formation [72]. This evidence concerns the gene PTPA and neurodegenerative disease.